These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17437017

  • 1. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC, Vukmirović-Popović S, Kalina M, Seidlitz E, Singh G.
    Br J Cancer; 2007 May 21; 96(10):1526-31. PubMed ID: 17437017
    [Abstract] [Full Text] [Related]

  • 2. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC, Popović SV, Lhoták S, Seidlitz E, Hirte HW, Tozer RG, Singh G.
    Cancer Res; 2002 Mar 15; 62(6):1588-91. PubMed ID: 11912125
    [Abstract] [Full Text] [Related]

  • 3. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 4. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 5. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.
    Cancer Biol Ther; 2009 Jun 01; 8(12):1109-16. PubMed ID: 19652526
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P.
    Cancer Res; 2007 Oct 15; 67(20):9894-902. PubMed ID: 17942921
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P.
    J Natl Cancer Inst; 2007 Feb 21; 99(4):322-30. PubMed ID: 17312309
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI.
    Br J Cancer; 2001 Apr 20; 84(8):1126-34. PubMed ID: 11308265
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T.
    Cancer Res; 1995 Aug 15; 55(16):3551-7. PubMed ID: 7627963
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ.
    Cancer Res; 2001 Jun 01; 61(11):4432-6. PubMed ID: 11389072
    [Abstract] [Full Text] [Related]

  • 13. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.
    Cancer Res; 2010 Oct 01; 70(19):7610-9. PubMed ID: 20841471
    [Abstract] [Full Text] [Related]

  • 14. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB.
    J Cancer Res Clin Oncol; 2015 Jun 01; 141(6):1025-36. PubMed ID: 25431338
    [Abstract] [Full Text] [Related]

  • 15. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
    Jeong J, Lee KS, Choi YK, Oh YJ, Lee HD.
    J Korean Med Sci; 2011 Dec 01; 26(12):1569-75. PubMed ID: 22147993
    [Abstract] [Full Text] [Related]

  • 16. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P.
    J Bone Miner Res; 2001 Nov 01; 16(11):2027-34. PubMed ID: 11697798
    [Abstract] [Full Text] [Related]

  • 17. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
    Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I.
    Int J Cancer; 2010 Jan 15; 126(2):522-32. PubMed ID: 19621384
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT, Holen I, Dear TN, Hunter K, Brown HK.
    Bone; 2014 Sep 15; 66(100):240-50. PubMed ID: 24971713
    [Abstract] [Full Text] [Related]

  • 20. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 15; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.